Name: Ann Lacasce, MD, MMSc discusses treatment in early stage high-risk cHL patients
Uploaded: 2025-01-09T00:00:00+00:00
Description: Ann Lacasce MD, MMSc, of Dana-Farber Cancer Institute presented findings at #ASH24 suggesting treatment with brentuximab vedotin and nivolumab can reduce toxicities and may decrease the need for radiation in early stage high-risk cHL patients.

Ann Lacasce MD, MMSc, of Dana-Farber Cancer Institute presented findings at #ASH24 suggesting treatment with brentuximab vedotin and nivolumab can reduce toxicities and may decrease the need for radiation in early stage high-risk cHL patients.

Related Presenters

Ann LaCasce, MD, MMSc

Medical Oncology

Ann LaCasce, MD, MMSc, Associate Professor of Medicine, is a lymphoma specialist and is the Director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology. She serves on the Alliance Lymphoma Committee, the National ...

View full profile